Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Regeneron Pharmaceuticals Company

REGN
US75886F1075
881535

Price

1,015.67
Today +/-
+15.22
Today %
+1.65 %
P

Regeneron Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Regeneron Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Regeneron Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Regeneron Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Regeneron Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Regeneron Pharmaceuticals Stock Price History

DateRegeneron Pharmaceuticals Price
10/11/20241,015.67 undefined
10/10/2024999.02 undefined
10/9/20241,012.19 undefined
10/8/20241,005.26 undefined
10/7/2024996.05 undefined
10/4/20241,012.82 undefined
10/3/20241,014.59 undefined
10/2/20241,040.27 undefined
10/1/20241,046.91 undefined
9/30/20241,051.24 undefined
9/27/20241,042.69 undefined
9/26/20241,039.96 undefined
9/25/20241,031.15 undefined
9/24/20241,045.98 undefined
9/23/20241,091.98 undefined
9/20/20241,145.03 undefined
9/19/20241,150.19 undefined
9/18/20241,138.81 undefined
9/17/20241,146.75 undefined
9/16/20241,153.08 undefined
9/13/20241,153.35 undefined

Regeneron Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Regeneron Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Regeneron Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Regeneron Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Regeneron Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Regeneron Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Regeneron Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Regeneron Pharmaceuticals’s growth potential.

Regeneron Pharmaceuticals Revenue, EBIT and net profit per share

DateRegeneron Pharmaceuticals RevenueRegeneron Pharmaceuticals EBITRegeneron Pharmaceuticals Net Income
2029e20.08 B undefined0 undefined8.14 B undefined
2028e18.94 B undefined7.89 B undefined7.38 B undefined
2027e17.88 B undefined7.19 B undefined6.78 B undefined
2026e16.7 B undefined6.66 B undefined6.17 B undefined
2025e15.69 B undefined5.94 B undefined5.5 B undefined
2024e14.45 B undefined5.31 B undefined5.07 B undefined
202313.12 B undefined4.34 B undefined3.95 B undefined
202212.17 B undefined4.99 B undefined4.34 B undefined
202116.07 B undefined8.95 B undefined8.08 B undefined
20208.5 B undefined3.58 B undefined3.51 B undefined
20197.86 B undefined2.21 B undefined2.12 B undefined
20186.71 B undefined2.53 B undefined2.44 B undefined
20175.87 B undefined2.08 B undefined1.2 B undefined
20164.86 B undefined1.33 B undefined896 M undefined
20154.1 B undefined1.25 B undefined636 M undefined
20142.82 B undefined823 M undefined338 M undefined
20132.11 B undefined760 M undefined424 M undefined
20121.38 B undefined458 M undefined750 M undefined
2011446 M undefined-205 M undefined-222 M undefined
2010459 M undefined-97 M undefined-104 M undefined
2009379 M undefined-74 M undefined-68 M undefined
2008238 M undefined-87 M undefined-79 M undefined
2007125 M undefined-115 M undefined-107 M undefined
200663 M undefined-108 M undefined-102 M undefined
200566 M undefined-124 M undefined-95 M undefined
2004174 M undefined6 M undefined42 M undefined

Regeneron Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000.010.010.010.020.020.020.030.040.030.060.020.020.060.170.070.060.130.240.380.460.451.382.112.824.14.865.876.717.868.516.0712.1713.1214.4515.6916.717.8818.9420.08
--300.0075.00--200.0014.29-16.6735.0040.74-10.5373.53-62.71-159.09205.26-62.07-4.5598.4190.4059.2421.11-2.83208.9752.7633.9745.5318.4220.8214.2917.178.0689.15-24.267.7510.158.626.437.035.976.01
-------100.0095.0088.8986.8491.1874.5868.1872.7389.4791.3886.3687.30100.00100.0099.7499.5699.1093.9092.5992.7390.4293.8593.2493.5390.0586.8284.8387.1886.93------
00000000.020.020.020.030.030.040.020.020.050.160.060.060.130.240.380.460.441.291.952.623.714.565.486.287.087.3813.6310.6111.4000000
-0-0-0-0.01-0.02-0.04-0.02-0.01-0.02-0.01-0.01-0.02-0.03-0.09-0.12-0.10.01-0.12-0.11-0.12-0.09-0.07-0.1-0.210.460.760.821.251.332.082.532.213.588.954.994.345.155.726.447.197.890
--400.00-100.00-142.86-328.57-600.00-104.76-45.83-110.00-51.85-34.21-70.59-42.37-395.45-554.55-175.443.45-187.88-171.43-92.00-36.55-19.53-21.13-45.9633.2436.1029.1830.5127.3935.4237.7628.1142.1055.6741.0333.0535.6636.4738.5540.2441.62-
-0-0-0-0-0.02-0.04-0.03-0.02-0.03-0.01-0.01-0.02-0.02-0.08-0.12-0.110.04-0.1-0.1-0.11-0.08-0.07-0.1-0.220.750.420.340.640.91.22.442.123.518.084.343.955.075.56.176.787.388.14
-200.00-33.33375.00110.53-22.50-22.5833.33-62.50-25.00155.56-230.4363.16-13.71-139.25-326.197.374.90-26.17-13.9252.94113.46-437.84-43.47-20.2888.1740.8833.82103.84-13.4266.02129.86-46.28-8.8828.138.6712.109.828.9710.25
101415151517192024293131354244505656586679808391115111113115116116115115115112114113.7000000
------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Regeneron Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Regeneron Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                     
0.010.020.10.080.090.050.050.080.090.090.070.120.390.260.290.30.30.460.770.480.340.250.530.310.690.91.051.041.412.813.213.595.77.7410.84
000000000.010.0100.01000.020.040.040.010.010.030.060.080.10.690.960.981.471.611.972.242.674.126.045.335.67
00111000000000001042300000000000000
00000000000.01000.010.0100000000.020.030.070.130.240.40.731.151.421.921.952.42.58
001020011121222233131119251917678125164131225243387161332411386.6
0.010.020.110.080.090.050.050.090.10.090.070.140.390.280.320.340.340.470.80.520.430.360.671.211.82.132.923.184.346.457.699.7814.0215.8819.48
000.010.010.020.030.030.030.030.030.040.040.040.080.080.070.060.050.060.140.260.350.370.380.530.971.592.082.362.582.893.223.483.764.22
000000.010.020.020.040.030.030.040.050.030.070.050.020.060.080.050.050.370.280.270.390.460.630.861.491.83.313.26.886.645.47
00000000000000000000000000000000000
0000000000000000000000000000000000.921.04
00000000000000000000000000000000000
0000000000000.010.010.010.010000.010.010.010.010.220.240.270.470.850.580.910.910.971.062.012.87
000.010.010.030.040.050.050.070.060.060.070.10.120.160.130.080.120.140.20.320.730.660.871.151.712.693.794.435.297.127.3911.4213.3313.6
0.010.020.110.10.120.090.090.140.170.160.140.210.50.390.480.470.420.580.940.720.741.091.322.082.953.845.616.978.7611.7414.817.1725.4429.2233.08
                                                                     
77000000000000000000000000000000000.1
00.020.120.120.170.170.190.270.310.310.310.410.570.570.670.680.70.91.251.31.341.581.761.762.052.453.13.033.513.914.436.728.099.9511.35
-0-0.01-0.01-0.03-0.07-0.1-0.13-0.16-0.17-0.18-0.2-0.22-0.3-0.42-0.53-0.49-0.59-0.69-0.79-0.87-0.94-1.05-1.27-0.52-0.090.220.851.752.955.257.3810.8918.9723.3127.26
00000-1-1-1-100-1-2-3-4-3-10001-2-2-1-1529-131-122129-26-239-80.9
00000000000000000000000000000000000
0.010.020.110.090.10.070.070.110.140.130.110.180.270.150.140.180.110.220.460.420.40.530.491.251.952.723.964.776.469.1511.8317.6427.0333.0238.53
00000.010.010.0100.010.010.010.010.020.030.020.020.020.010.010.020.020.020.030.040.060.10.140.140.180.220.420.480.560.594.43
000000000000000000.010.020.020.030.030.070.070.190.380.50.510.640.751.041.51.882.072.36
01111103443547104015172447484555535147171167471321473641720768478458.9
000000000000001400000000000000000000
00012334211100000020000001100127000072000
0000.010.010.020.010.010.010.010.010.010.020.040.070.030.040.050.280.080.090.110.150.160.30.660.811.241.141.442.12.73.933.147.24
0.010.0100.010.010.010.010.0100000.20.20.20.20.20.200.050.110.160.440.460.510.460.360.350.70.710.712.71.982.72.7
00000000000000000000000000000000000
0000007131513111075695669123192165142293255216196175780931781826905745754708980.8
0.010.0100.010.010.010.010.020.020.020.010.010.210.210.270.260.270.320.190.220.250.450.690.670.70.631.141.281.481.541.623.442.733.413.68
0.010.010.010.010.020.030.030.030.030.030.030.030.230.250.340.290.310.370.480.30.350.560.840.8411.291.952.522.622.983.726.146.676.5510.93
0.010.030.110.10.120.090.090.140.170.160.140.210.50.390.480.470.420.580.940.730.741.091.332.082.954.015.927.299.0812.1315.5523.7833.739.5749.46
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Regeneron Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Regeneron Pharmaceuticals's financial health and stability.

Assets

Regeneron Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Regeneron Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Regeneron Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Regeneron Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0-0-0-0-0.02-0.04-0.03-0.02-0.03-0.01-0.01-0.02-0.02-0.08-0.12-0.110.04-0.1-0.1-0.11-0.08-0.07-0.1-0.220.750.420.340.640.91.22.442.123.518.084.343.95
00002345643346812151514111114193136415274104145148210235286341421
000000000000000000000000-34063-53-121-360318-140-13075-147-746-837
001-110-4-14-8-2-71-1511384-58279388-56-49140-18-672-19015229240-926-697-200-1,503-1,916-243-94
00-0-0-000.010.010.010000.01000-0.020.020.020.060.070.060.080.120.250.460.720.971.161.080.870.90.731.392.052.04
0000011100000011111111111192121421232010518222523555373
000000000000000000000000000.060.280.480.750.210.340.191.221.50.87
0-0-0-0.01-0.02-0.03-0.02-0.02-0.02-0.01-0.01-0.01-0.03-0.06-0.11-0.01-0.02-0.030.020.03-0.09-0.070.1-0.14-0.070.580.751.331.491.312.22.432.627.085.014.59
00-2-1-3-11-6-3-8-2-3-5-6-8-34-29-6-5-2-18-34-97-99-57-49-156-333-677-511-272-383-429-614-551-1,616-926
0-2-2-778-19317-44-38217-57-75-58-4910115-155-8530-2-437128-81-355-420-907-1,046-1,005-1,463-2,027-70-5,384-3,784-3,185
0-10-7511-83810-35-36522-51-67-24-2016120-152-676595-337185-31-199-87-229-534-732-1,079-1,598544-4,832-2,167-2,258
000000000000000000000000000000000000
00000-00-0-0-0-0-0-00.1900.010000-0.20.020.050.39-0-0-0.22-0.14-0.040.04001.98000
6414910510237043019415829404185319782001376357126206126240110-64-3,27126-563-1,089
61015910490196639-1092349110844185319-19231243384-9777-218-262-700-24-77-252-1,970-1,005-1,009-1,790
0500000000000000000000-3-142-15921-122-328-786-301-187-188-680-1,032-445-700
000000000000000000000000000000000000
5497-9-31191-5-937216-16752-28953261-251-40-94371-253305113160-261277655150577690221-381
-1.4-3.8-5.2-9.1-20.2-44.9-27.4-21.5-28.9-8.2-13.2-19.2-34.4-65.5-144.9-35.8-23.1-35.320.39-124-167.2-0.5-198.9-123.9427.3419.4652.99741,034.51,8122,000.42,003.56,529.43,3983,667.6
000000000000000000000000000000000000

Regeneron Pharmaceuticals stock margins

The Regeneron Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Regeneron Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Regeneron Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Regeneron Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Regeneron Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Regeneron Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Regeneron Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Regeneron Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Regeneron Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Regeneron Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Regeneron Pharmaceuticals Margin History

Regeneron Pharmaceuticals Gross marginRegeneron Pharmaceuticals Profit marginRegeneron Pharmaceuticals EBIT marginRegeneron Pharmaceuticals Profit margin
2029e86.94 %0 %40.54 %
2028e86.94 %41.62 %38.98 %
2027e86.94 %40.24 %37.91 %
2026e86.94 %39.87 %36.94 %
2025e86.94 %37.82 %35.07 %
2024e86.94 %36.77 %35.06 %
202386.94 %33.05 %30.14 %
202287.18 %41.03 %35.64 %
202184.83 %55.67 %50.24 %
202086.82 %42.1 %41.34 %
201990.05 %28.11 %26.91 %
201893.53 %37.76 %36.42 %
201793.24 %35.42 %20.42 %
201693.85 %27.39 %18.44 %
201590.42 %30.51 %15.5 %
201492.73 %29.18 %11.99 %
201392.59 %36.1 %20.14 %
201293.9 %33.24 %54.43 %
201199.1 %-45.96 %-49.78 %
201099.56 %-21.13 %-22.66 %
200999.74 %-19.53 %-17.94 %
2008100 %-36.55 %-33.19 %
2007100 %-92 %-85.6 %
200687.3 %-171.43 %-161.9 %
200586.36 %-187.88 %-143.94 %
200491.38 %3.45 %24.14 %

Regeneron Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Regeneron Pharmaceuticals earnings per share therefore indicates how much revenue Regeneron Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regeneron Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regeneron Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regeneron Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regeneron Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Regeneron Pharmaceuticals Revenue, EBIT and net profit per share

DateRegeneron Pharmaceuticals Sales per ShareRegeneron Pharmaceuticals EBIT per shareRegeneron Pharmaceuticals Earnings per Share
2029e182.19 undefined0 undefined73.86 undefined
2028e171.86 undefined0 undefined67 undefined
2027e162.18 undefined0 undefined61.48 undefined
2026e151.53 undefined0 undefined55.97 undefined
2025e142.38 undefined0 undefined49.94 undefined
2024e131.07 undefined0 undefined45.95 undefined
2023115.37 undefined38.13 undefined34.77 undefined
2022106.78 undefined43.81 undefined38.05 undefined
2021143.5 undefined79.88 undefined72.1 undefined
202073.89 undefined31.1 undefined30.55 undefined
201968.37 undefined19.22 undefined18.4 undefined
201858.36 undefined22.03 undefined21.25 undefined
201750.62 undefined17.93 undefined10.34 undefined
201641.9 undefined11.47 undefined7.72 undefined
201535.69 undefined10.89 undefined5.53 undefined
201424.96 undefined7.28 undefined2.99 undefined
201318.96 undefined6.85 undefined3.82 undefined
201211.98 undefined3.98 undefined6.52 undefined
20114.9 undefined-2.25 undefined-2.44 undefined
20105.53 undefined-1.17 undefined-1.25 undefined
20094.74 undefined-0.93 undefined-0.85 undefined
20083.01 undefined-1.1 undefined-1 undefined
20071.89 undefined-1.74 undefined-1.62 undefined
20061.09 undefined-1.86 undefined-1.76 undefined
20051.18 undefined-2.21 undefined-1.7 undefined
20043.11 undefined0.11 undefined0.75 undefined

Regeneron Pharmaceuticals business model

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Regeneron Pharmaceuticals revenue by segment

In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Medicines

Regeneron Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Regeneron Pharmaceuticals Revenue by Segment

Segmente202320222021202020192018
Net product sales7.08 B USD6.89 B USD12.12 B USD---
Collaboration revenue5.5 B USD-1.77 B USD---
Product---5.57 B USD--
Sanofi collaboration revenue-2.86 B USD----
Other collaboration revenue-2.06 B USD----
Product and service, other---557 M USD-947.3 M USD
Other revenue536.1 M USD365.1 M USD281.2 M USD---
Libtayo----175.7 M USD-
EYLEA-6.26 B USD5.79 B USD4.95 B USD--
REGEN-COV--5.83 B USD185.7 M USD--
Product and service, other----1.19 B USD-
Libtayo-73 M USD306.3 M USD270.7 M USD-14.8 M USD
Praluent-130 M USD170 M USD150.9 M USD--
Evkeeza-48.6 M USD18.4 M USD---
ARCALYST--2.2 M USD13.1 M USD--
Inmazeb-3 M USD----
Product----4.83 B USD-
Reimbursement for manufacturing of commercial supplies111.1 M USD91.4 M USD60.1 M USD---
Sales-based milestones earned50 M USD100 M USD50 M USD---
Reimbursement of commercialization-related expenses-41.4 M USD89.6 M USD---
Sales-based milestone earned---50 M USD--
Reimbursements of R&D expenses, net of Regeneron's obligation for its share of Sanofi R&D expenses-43 M USD----
Reimbursement of research and development expenses--42.4 M USD---
Amounts recognized in connection with up-front payments received-33.3 M USD----
Other-28.7 M USD----
Amounts recognized in connection with up-front and development milestone payments received--26.2 M USD---
Reimbursement of R&D expenses-1.5 M USD6.8 M USD----
Regeneron's share of profits in connection with commercialization of antibodies-6.7 M USD-13.6 M USD---
Regeneron's obligation for its share of Sanofi research and development expenses---40.9 M USD---
Regeneron's obligation for its share of Sanofi commercial expenses--19.9 M USD-36.3 M USD---
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses-83.7 M USD-----
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits--70.1 M USD-133 M USD---
EYLEA----4.64 B USD-
Product-----4.11 B USD
Regeneron's share of profits in connection with commercialization of EYLEA outside the United States1.38 B USD1.32 B USD----
One-time payment in connection with change in Japan arrangement-21.9 M USD----
ARCALYST----14.5 M USD-
Regeneron's obligation for its share of Bayer R&D expenses--34.3 M USD----
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses-44 M USD-----
EYLEA-----4.08 B USD
Regeneron's net profit in connection with commercialization of EYLEA outside the United States--1.35 B USD---
ARCALYST-----14.7 M USD
Ronapreve------
Other-13.3 M USD-----
Amounts recognized in connection with up-front and development milestone payments received---210.6 M USD--
"Next Generation" Covid Antibodies50.4 M USD-----
Reimbursement of research and development expenses---46.7 M USD--
Ronapreve------
Libtayo863.1 M USD-----
Casirivimab and imdevimab--259.6 M USD---

Regeneron Pharmaceuticals Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Regeneron Pharmaceuticals Revenue by Segment

DateUnited States
20226.89 B USD
202112.12 B USD

Regeneron Pharmaceuticals SWOT Analysis

Strengths

Regeneron Pharmaceuticals Inc has several strengths that contribute to its success in the market. These strengths include:

  • Strong Research and Development: Regeneron has a robust research and development pipeline, allowing for the development of innovative pharmaceutical products.
  • Diverse Product Portfolio: The company offers a wide range of drugs targeting various therapeutic areas, reducing its reliance on a single product.
  • Partnerships and Collaborations: Regeneron has established strategic partnerships with other pharmaceutical companies, enabling access to new technologies and markets.
  • Strong Financial Performance: The company has consistently demonstrated strong financial performance, with steady revenue growth and profitability.

Weaknesses

Despite its strengths, Regeneron Pharmaceuticals Inc also has certain weaknesses that need to be addressed. These weaknesses include:

  • Heavy Dependence on Key Products: The company relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to market fluctuations and patent expirations.
  • Regulatory Risks: As a pharmaceutical company, Regeneron is subject to strict regulatory approvals and potential delays, which can impact product launches and timelines.
  • High Research and Development Costs: Developing innovative drugs involves substantial investment, making it essential for the company to maintain a steady stream of successful product launches.

Opportunities

Regeneron Pharmaceuticals Inc can capitalize on several opportunities to further enhance its market position. These opportunities include:

  • Expanding Global Markets: The pharmaceutical industry offers significant growth opportunities in emerging markets, enabling the company to tap into new patient populations and revenue streams.
  • Increasing Demand for Biologics: The growing demand for biologic drugs presents an opportunity for Regeneron, given its expertise in developing and manufacturing biologic pharmaceuticals.
  • Research Collaboration: Collaborating with academic institutions and research organizations can lead to breakthrough discoveries and potential partnerships for innovative drug development.

Threats

Regeneron Pharmaceuticals Inc also faces certain threats that could impact its business and growth prospects. These threats include:

  • Intense Competition: The pharmaceutical industry is highly competitive, with the presence of numerous prominent players. This poses a threat to the company's market share and pricing power.
  • Pricing and Reimbursement Pressures: Efforts to control healthcare costs and reimbursement policies can impact the pricing and profitability of pharmaceutical products.
  • Intellectual Property Challenges: Regeneron faces the risk of patent expirations and potential legal challenges from generic drug manufacturers, which can lead to a loss of market exclusivity.

Regeneron Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Regeneron Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Regeneron Pharmaceuticals shares outstanding

The number of shares was Regeneron Pharmaceuticals in 2023 — This indicates how many shares 113.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Regeneron Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Regeneron Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Regeneron Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regeneron Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202410.83 11.56  (6.79 %)2024 Q2
3/31/202410.29 9.55  (-7.23 %)2024 Q1
12/31/202310.95 11.86  (8.36 %)2023 Q4
9/30/202310.93 11.59  (6.01 %)2023 Q3
6/30/202310.04 10.24  (1.99 %)2023 Q2
3/31/20239.75 10.09  (3.5 %)2023 Q1
12/31/202210.23 12.56  (22.77 %)2022 Q4
9/30/20229.67 11.14  (15.25 %)2022 Q3
6/30/20229.02 9.77  (8.33 %)2022 Q2
3/31/20229.93 8.93  (-10.09 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Regeneron Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

69

👫 Social

99

🏛️ Governance

24

Environment

Scope 1 - Direct Emissions
65,800
Scope 2 - Indirect emissions from purchased energy
46,400
Scope 3 - Indirect emissions within the value chain
689,242
Total CO₂ emissions
112,200
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees66
White Management Share64
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Regeneron Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.06191 % Fidelity Management & Research Company LLC9,988,945435,05712/31/2023
7.97657 % The Vanguard Group, Inc.8,792,57539,50512/31/2023
5.13826 % BlackRock Institutional Trust Company, N.A.5,663,900-283,71212/31/2023
5.07177 % JP Morgan Asset Management5,590,613-169,90712/31/2023
4.65435 % Capital World Investors5,130,48523,14612/31/2023
4.44639 % State Street Global Advisors (US)4,901,25172,14512/31/2023
2.64535 % Capital International Investors2,915,972-58,36612/31/2023
2.14795 % Dodge & Cox2,367,680-5,31812/31/2023
2.13573 % Geode Capital Management, L.L.C.2,354,21734,23112/31/2023
1.83981 % Invesco Capital Management (QQQ Trust)2,028,0196,9923/31/2024
1
2
3
4
5
...
10

Regeneron Pharmaceuticals Executives and Management Board

Dr. Neil Stahl66
Regeneron Pharmaceuticals Executive Vice President - Research and Development
Compensation 9.14 M
Mr. Andrew Murphy65
Regeneron Pharmaceuticals Executive Vice President - Research
Compensation 9.12 M
Mr. Daniel Van Plew50
Regeneron Pharmaceuticals Executive Vice President, General Manager - Industrial Operations and Product Supply
Compensation 8.85 M
Mr. Joseph LaRosa64
Regeneron Pharmaceuticals Executive Vice President, General Counsel, Secretary
Compensation 7.13 M
Dr. Leonard Schleifer70
Regeneron Pharmaceuticals Co-Chairman of the Board, President, Chief Executive Officer, Founder (since 1988)
Compensation 7 M
1
2
3
4
...
5

Regeneron Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Teva Pharmaceutical Inds Stock
Teva Pharmaceutical Inds
SupplierCustomer0,890,970,760,59-0,42-0,44
Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals
SupplierCustomer0,890,810,430,18-0,010,43
AmerisourceBergen Corporation Stock
AmerisourceBergen Corporation
SupplierCustomer0,860,890,940,650,670,53
Bayer Stock
Bayer
SupplierCustomer0,860,880,910,740,400,20
Zoetis Inc. Stock
Zoetis Inc.
SupplierCustomer0,860,87-0,16-0,320,230,47
Mitsubishi Chemical Holdings Corporation Stock
Mitsubishi Chemical Holdings Corporation
SupplierCustomer0,780,67-0,280,22--
Sanofi Stock
Sanofi
SupplierCustomer0,750,270,350,500,24-
Kiniksa Pharmaceuticals A Stock
Kiniksa Pharmaceuticals A
SupplierCustomer0,690,930,27-0,16-0,48-0,49
Ultragenyx Pharmaceutical Stock
Ultragenyx Pharmaceutical
SupplierCustomer0,680,930,750,25-0,37-0,74
McKesson Corporation Stock
McKesson Corporation
SupplierCustomer0,670,780,910,670,670,52
1
2
3
4

Most common questions regarding Regeneron Pharmaceuticals

What values and corporate philosophy does Regeneron Pharmaceuticals represent?

Regeneron Pharmaceuticals Inc is a leading biotechnology company that values innovation, integrity, and collaboration. With a corporate philosophy centered around science-driven discoveries and patient-focused solutions, Regeneron aims to improve lives through its research and development of therapeutic products. They prioritize the use of cutting-edge technologies to address unmet medical needs and strive to deliver impactful medicines to patients worldwide. Regeneron's commitment to transparency, ethical practices, and scientific excellence has established its reputation as a trusted and reliable healthcare partner.

In which countries and regions is Regeneron Pharmaceuticals primarily present?

Regeneron Pharmaceuticals Inc primarily operates in various countries and regions around the world. The company has a global presence with key markets in the United States, Europe, and other international locations. Through its strong partnerships and collaborations, Regeneron has expanded its reach and established a significant presence in the biopharmaceutical industry. With its dedication to scientific innovation and breakthrough treatments, Regeneron Pharmaceuticals Inc continues to make a meaningful impact on patients' lives worldwide.

What significant milestones has the company Regeneron Pharmaceuticals achieved?

Regeneron Pharmaceuticals Inc. has achieved several significant milestones since its inception. Notably, the company received FDA approval for its groundbreaking drug, EYLEA®, in 2011, which revolutionized the treatment of age-related macular degeneration. Regeneron also gained recognition for the development of its therapy, Dupixent®, for atopic dermatitis, asthma, and other allergic conditions. In addition, the company has made significant advancements in the field of immuno-oncology with its innovative drug, Libtayo®, approved for the treatment of certain types of skin and lung cancers. Regeneron continues to drive progress in the biopharmaceutical industry by focusing on novel research and development initiatives.

What is the history and background of the company Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals Inc, founded in 1988, is a renowned American biotechnology company specializing in the discovery, development, and commercialization of innovative medicines. Headquartered in Tarrytown, New York, Regeneron has a rich history of pioneering scientific breakthroughs. The company's success can be attributed to its robust research and development initiatives, focusing on various therapeutic areas such as oncology, ophthalmology, cardiovascular diseases, and rare genetic disorders. Regeneron's remarkable achievements include the development of EYLEA® (a leading treatment for retinal diseases) and the groundbreaking antibody cocktail, REGN-COV2, used for COVID-19 treatment. Renowned for its dedication to rigorous scientific research, Regeneron Pharmaceuticals Inc has established itself as a leader in the biopharmaceutical industry.

Who are the main competitors of Regeneron Pharmaceuticals in the market?

The main competitors of Regeneron Pharmaceuticals Inc in the market include major pharmaceutical companies like Roche Holding AG, Amgen Inc, and Pfizer Inc. These companies are also involved in the development and commercialization of biopharmaceutical products, competing within the same therapeutic areas as Regeneron.

In which industries is Regeneron Pharmaceuticals primarily active?

Regeneron Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of Regeneron Pharmaceuticals?

The business model of Regeneron Pharmaceuticals Inc. revolves around the research, development, and commercialization of innovative biopharmaceutical products. Regeneron focuses on discovering, designing, and manufacturing novel medicines that address unmet medical needs. The company employs advanced technologies, including monoclonal antibody platforms and genetically modified mice, to develop therapies across various therapeutic areas, such as ophthalmology, oncology, and inflammatory diseases. By continuously investing in research and strategic collaborations, Regeneron strives to deliver life-changing treatments, improve patient outcomes, and become a leading force in the biopharmaceutical industry. Visit our website for more information about Regeneron Pharmaceuticals Inc. and its business model.

What is the P/E ratio of Regeneron Pharmaceuticals 2024?

The Regeneron Pharmaceuticals P/E ratio is 22.8.

What is the P/S ratio of Regeneron Pharmaceuticals 2024?

The Regeneron Pharmaceuticals P/S ratio is 7.99.

What is the Quality Investing of Regeneron Pharmaceuticals?

The Quality Investing for Regeneron Pharmaceuticals is 8/10.

What is the revenue of Regeneron Pharmaceuticals 2024?

The expected Regeneron Pharmaceuticals revenue is 14.45 B USD.

How high is the profit of Regeneron Pharmaceuticals 2024?

The expected Regeneron Pharmaceuticals profit is 5.07 B USD.

What is the business model of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology company based in the United States that focuses on researching, developing, and marketing medications. It was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into various business divisions that address different medical conditions. This includes the field of ophthalmology, where Regeneron has developed the medication Eylea®, an effective treatment for age-related macular degeneration and other eye diseases. The sales in this area amounted to approximately $7.7 billion in 2020. Another important area is oncology, where Regeneron has developed the cancer medication Libtayo®, which is used to treat skin cancer and lung cancer. The sales in this area amounted to approximately $340 million in 2020. Regeneron is also involved in inflammation diseases, genetic diseases, and infectious diseases. The company has several promising medications in development in these areas, including a treatment for COVID-19. Regeneron collaborates closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with whom Regeneron has already brought several successful medications to the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, the R&D expenditure amounted to approximately $3.7 billion, which is about 40 percent of the total revenue. The company employs a large number of scientists and researchers who are constantly working on new medications. Regeneron also values the promotion of young talent. The company has established an extensive scholarship program specifically targeted at students and young scientists. This ensures that highly qualified professionals will be available in the future to further advance the company. In summary, Regeneron's business model specializes in research and development of new medications. The company works closely with various partners and has already brought several promising medications to the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers. Regeneron Pharmaceuticals is a US biotechnology company that specializes in the research, development, and marketing of medications. The company was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into several business areas that deal with different medical conditions. This includes the field of ophthalmology, in which Regeneron has developed the effective drug Eylea® for age-related macular degeneration and other eye diseases. Sales in this area were around $7.7 billion in 2020. Another important area is oncology, in which Regeneron has developed the cancer drug Libtayo®, which is used to treat skin cancer and lung cancer. Sales in this area were around $340 million in 2020. Other business areas of Regeneron include inflammatory diseases, genetic diseases, and infectious diseases. In these areas, the company has already developed several promising drugs, including a treatment for COVID-19. Regeneron works closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with which Regeneron has already successfully launched several drugs on the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, R&D spending was around $3.7 billion, approximately 40 percent of total revenue. The company employs a large number of scientists and researchers who are constantly working on new drugs. Regeneron also places great importance on promoting young talent. The company has launched an extensive scholarship program specifically targeting students and young scientists. This is to ensure that highly qualified professionals are available in the future to further advance the company. In conclusion, Regeneron's business model specializes in the research and development of new medications. The company works closely with various partners and has already launched several promising drugs on the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers.

What is the Regeneron Pharmaceuticals dividend?

Regeneron Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Regeneron Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Regeneron Pharmaceuticals or the company does not pay out a dividend.

What is the Regeneron Pharmaceuticals ISIN?

The ISIN of Regeneron Pharmaceuticals is US75886F1075.

What is the Regeneron Pharmaceuticals WKN?

The WKN of Regeneron Pharmaceuticals is 881535.

What is the Regeneron Pharmaceuticals ticker?

The ticker of Regeneron Pharmaceuticals is REGN.

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.

All fundamentals about Regeneron Pharmaceuticals

Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.